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Abstract
Background: The vast majority of patients with systemic lupus erythematosus (SLE) complain about fatigue. They
also report fatigue as one of their most debilitating symptoms. Yet, in clinical practice, fatigue is only rarely assessed
and remains poorly understood. The purpose of this study is to validate the Fatigue Assessment Scale (FAS) and
assess the impact of disease activity on fatigue in SLE.
Methods: A cross-sectional single-center study of patients was included in the Swiss SLE Cohort Study. The FAS
and the Short Form 36 (SF-36) were administered to SLE patients and controls with primary Sjogren’s syndrome
(pSS) and healthy volunteers (HV) attending our clinic. Disease activity in SLE was captured at the same time as
patient-reported outcomes using the SLE Disease Activity Index score with the Safety of Estrogens in SLE National
Assessment modification (SELENA-SLEDAI) and the physician’s global assessment. We explored the internal consistency,
reproducibility, construct validity, and convergence of the FAS, in comparison to the vitality subscale (VT) of the SF-36. We
examined the association of FAS with demographics, disease type, SLE disease activity, and clinical features.
Results: Of the 73 SLE subjects, 89% were women and 77% were Caucasians. The median age was 43 years, and 23 (32%)
patients had active SLE. Demographics in pSS and HV were similar. Within the SLE group, FAS displayed good internal
consistency (Cronbach’s alpha = 0.93), unidimensionality, and test-retest reliability (ICC = 0.90). FAS and VT correlated well.
The total FAS was highest in active SLE and pSS and higher in non-active SLE compared to HV.
Conclusion: The FAS is a promising tool to measure fatigue in SLE. Patients with SLE display a significantly higher level of
fatigue than HV, which is even more pronounced in active disease and comparable to fatigue levels measured in pSS.
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Key messages
 This study is the first to validate the Fatigue
Assessment Scale (FAS) as a reliable and simple tool
to assess fatigue in systemic lupus erythematosus.
 Fatigue assessed by FAS correlates with global
disease activity in systemic lupus erythematosus.
 Fatigue levels in active systemic lupus erythematosus
are comparable to those in matched controls with
Sjogren’s syndrome.
Background
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease with a wide spectrum of clinical and
biological manifestations. The multiple dysfunctions in
the innate and adaptive immune system that ultimately
lead to autoimmunity and inflammation are thought to
be triggered by various environmental factors in genetic-
ally susceptible individuals [1]. The vast majority of SLE
patients complain about fatigue [2, 3] and report it as
one of the most debilitating disease features [4, 5].
Whether fatigue reflects SLE disease activity is still a
matter of debate [6]. Lupus fatigue has important reper-
cussions on daily activities and is associated with poor
quality of life (QoL) [7]. By using a qualitative interview
tool, Sterling et al. highlighted its negative impact on
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emotional, cognitive, professional, and social status [8].
Given its major role on patient’s morbidity, fatigue is an
essential aspect to consider in SLE management. Yet, fa-
tigue remains poorly understood by both health care
providers and the patient’s entourage [9].
Multiple instruments for assessing fatigue and various
definitions are available, without one standing out for its
simplicity and reliability. Thus, fatigue is difficult to
evaluate in daily practice and to standardize across stud-
ies for research purposes. The Fatigue Assessment Scale
(FAS) is a simple 10-item self-reported questionnaire de-
signed by Michielson et al. to assess fatigue in the gen-
eral population and validated subsequently in the
sarcoidosis setting [10, 11]. The FAS is derived from a
pool of 40 items selected in four previous valid question-
naires: the Fatigue Scale, the Checklist Individual
Strength, the Emotional Exhaustion subscale of the
Dutch version of the Maslach Burnout Inventory, and
the Energy and Fatigue subscale of the World Health
Organization Quality of Life assessment instrument. The
face validity was studied through a semantical analysis in
order to guide the selection of items. The FAS is report-
edly a unidimensional scale measuring fatigue independ-
ently from depression [12]. It has proven to be a reliable
and valid tool as well as sensitive to change in sarcoid-
osis patients [13]. Owing to its good psychometric prop-
erties in this specific disease, this instrument was then
used in a placebo-controlled randomized clinical trial
evaluating the effect of N-acetylcysteine on fatigue in
SLE [14, 15]. However, the reliability and validity of FAS
in SLE patients have yet to be demonstrated. In this
study, the primary objective was to study the construct,
the convergent validity, and test-retest correlation of the
FAS in SLE patients. Secondary objectives were to com-
pare the fatigue score between SLE patients, non-SLE
patients, and healthy volunteers; to measure perceived
fatigue in SLE patients with active and inactive disease;
and to determine whether other factors contribute to
fatigue.
Methods
Study population
Participants were aged ≥ 18 years old and attended the
Centre Hospitalier Universitaire Vaudois (CHUV) in
Lausanne between June 2015 and July 2016. All were in-
cluded in the Swiss Systemic Lupus Erythematosus Co-
hort Study (SSCS) [16, 17]. All SLE patients fulfilled the
revised American College of Rheumatology (ACR) cri-
teria and/or the Systemic Lupus International Collabor-
ating Clinics (SLICC) criteria [18, 19]. Control groups
consisted of patients with primary Sjogren syndrome
(pSS) meeting the 2002 American-European Classifica-
tion Criteria [20] and age- and gender-matched healthy
volunteers (HV). Patients with completed FAS and
SF-36 forms were retained for the cross-sectional study.
Patients with pSS were asked to participate in the cohort
study during their regular clinical follow-up. The HV
were recruited by public notice in the CHUV and were
evaluated medically to confirm the good health and ab-
sence of autoimmune disease or immunomodulatory
treatment. The protocol was approved by the Canton
Vaud ethical committee. All participants gave their writ-
ten informed consent, and the study was carried out in
compliance with the Helsinki Declaration.
Data collection and instruments
Data on patient’s age, sex, ethnicity, educational status,
tobacco use, body mass index (BMI), disease duration
since diagnosis, activity and damage, and treatment mo-
dalities were collected during the medical visit. Disease
activity in SLE was assessed by the SLE Disease Activity
Index with the Safety of Estrogens in Lupus Erythemato-
sus National Assessment modification (SELENA-SLE-
DAI) [21]. This score is based on 24 clinical and
biological items, which reflect disease activity within the
past month. Disease activity was also evaluated using the
Physician’s Global Assessment score (PGA) with a
4-point-Likert-scale ranging from 0 (inactive) to 3 (very
active disease) [21]. Patients with a SELENA-SLEDAI ≥ 4
and a PGA ≥ 1 were considered to have active disease
[22]. Damage was assessed in SLE with the SLICC/ACR
Damage Index (SDI) [23]. Disease-modifying treatment
(DMARD) at study visit and in the 4 weeks before was
classified into three groups: systemic glucocorticoids, an-
timalarials, and immunosuppressants. Data on
health-related quality of life (HRQoL) and fatigue were
assessed with the Short Form 36 (SF36) and the FAS in
all participants. The SF36 is a widely used health survey
form measuring 8 dimensions of QoL; each of them
ranges from 0 to 100 with lower scores reflecting poorer
health. The SF-36 vitality subscale (VT-SF36) is used for
convergent validity of fatigue questionnaires [24]. The
mental health subscale of the SF-36 (MH-SF36) was
used for the discriminant validity. The FAS comprises 10
questions with answers varying from never to always on
a 5-point-scale. The total FAS score ranges from 10 to
50, increasing proportionally to fatigue. Both question-
naires were completed by participants during the study
visit. A sample of 30 SLE patients was asked to complete
the FAS 2 weeks after the first assessment. These pa-
tients were reminded by text messages to complete and
send back the questionnaire after 2 weeks with a
pre-stamped envelope. Eligibility for this test-retest study
was a completed form, and the absence of important
intercurring events reported by the patient that would
influence the state of fatigue during the test-retest
period. FAS, SF-36, demographical data, and clinical data
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were collected in the two control groups of pSS patients
and HV.
Statistical procedure
Descriptive statistics were presented as absolute count and
percent for qualitative data and as median and interquartile
range (IQR) for quantitative. Difference between groups
and correlations were evaluated using non-parametric tests.
The psychometric properties of the FAS were evaluated
using the following methods. Cronbach’s alpha was calcu-
lated to measure the reliability of the tool by looking at
inter-item consistency. This measure is generally consid-
ered satisfactory if the alpha value is above 0.7 for
group-level analysis but a value above 0.9 is desirable for in-
dividual patients in clinical application [25]. A factor ana-
lysis was performed using the principal component analysis
(PCA) based on Kaiser criteria (eigenvalue > 1) and visual
inspection of the scree plot. A PCA was used with the FAS
and the MH-SF36 in order to examine the divergent valid-
ity (construct validity) of the FAS. Factor analysis extraction
was presented with an oblimin rotation. A coefficient factor
above 0.3 was considered significant. As there were slightly
less than 5 (4.87) patients per item for this measure, we
confirmed the results on a larger sample using SLE, pSS,
and HV. The convergent validity was examined with a
Spearman’s rho correlation between FAS and VT-SF36.
The test-retest reliability was measured using intraclass cor-
relations (ICC). A linear regression model was used for
multivariable analysis, with total FAS score as dependent
variable and disease activity and corticoid use as independ-
ent variables. P values < 0.05 were considered significant.
All statistics were performed on IBM SPSS statistics 24
(IBM Corp Armonk, NY) and GraphPad Prism 7 (Graph-
Pad Software, La Jolla, CA, USA).
Results
Group characteristics
Seventy-three patients with SLE, 23 patients with pSS,
and 23 healthy volunteers were included (Table 1). There
was no statistical difference in demographic features be-
tween groups. SLE subjects were predominantly women
(89%), of Caucasian origin (77%) and had a median age
of 43 years at assessment. Median disease duration from
diagnosis was 7 (3–15) years in patients with SLE com-
pared to 1 (0–2) in those with pSS (p < 0.001). Patients
with SLE were more frequently treated with systemic
corticosteroids and immunosuppressant drugs compared
to those with pSS. Among SLE patients treated with im-
munosuppressants, four had received cyclophosphamide
in the month preceding the study. Within the SLE
group, 23 (32%) had active disease (SELENA-SLEDAI ≥
4 and PGA ≥ 1). Table 2 compares the characteristics of
SLE patients according to their disease activity.
Psychometric analysis of FAS
The internal consistency of the FAS was measured at
0.93 (Cronbach’s alpha coefficient), and none of the
items would have improved the internal consistency if
removed. Principal component analysis favored a
one-component solution, confirmed by visual inspection
of the scree plot (Fig. 1). The factor analysis of FAS
items extracted a unique factor explaining 64% of the
variance with the items loading between 0.68 (item 3)
and 0.88 (item 5).
Of the 73 SLE subjects, 30 (41%) had a test-retest as-
sessment. Seven patients were excluded because of a
self-reported significant event between the first and the
second FAS assessment. There was no difference in age,
sex, ethnicity, and disease activity between the whole
Table 1 Patient’s and volunteer’s characteristics
All SLE (n = 73) pSS (n = 23) HV (n = 23) p value§
Age, median (IQR) years 43 (34–57) 44 (33–58) 34 (22–49) 0.44
Female sex (%) 65 (89) 21 (91) 20 (87) 0.89
Caucasian, no. (%) 56 (77) 19 (83) 20 (87) 0.53
Higher education*, no./total (%) 30/59 (51) 10/22 (45) 10/23 (43) 0.80
Active smoker, no. (%) 17 (23) 4 (17) 8 (35) 0.37
Body mass index, median (IQR) 23 (20–28) 25 (22–28) 22 (20–24) 0.48
Use of psychiatric medication£, no. (%) 14 (19) 8 (34) 3 (13) 0.16
Time from diagnosis, median (IQR) years 7 (3–15) 1 (0–2) – < 0.01
Immunomodulators past month, no. (%) 64 (88) 16 (70) – 0.04
Antimalarials, no. (%) 52 (71) 14 (61) – 0.35
Systemic corticosteroids, no. (%) 39 (53) 5 (22) – 0.01
Immunosuppressants, no (%) 35 (48) 5 (22) – 0.03
SLE systemic lupus erythematosus, pSS primary Sjogren syndrome, HV healthy volunteers, IQR interquartile range
*Defined as higher professional or technical school or university degree
£Defined as any antidepressants, antipsychotics, and anxiolytics/hypnotics
§p value < 0.05 is considered significant
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SLE sample and the test-retest subjects (data not
shown). The test-retest correlation was good with an
ICC of 0.90 (95%CI 0.80–0.95, p < 0.001) for a 2-week
interval. The FAS correlated strongly with the VT-SF36
subscale (rs = 0.85, p < 0.001). The FAS correlation with
the MH-SF36 was rs = 0.65 (p < 0.001). The PCA on the
combined pool of the FAS and the MH-SF36 items fa-
vored a two-component solution (eigenvalue factor I,
8.4; factor II, 1.9; percentage explained variance, 69%).
One statement of the ten FAS items (FAS-7) loaded
higher on the mental health scale. All other items loaded
higher on the fatigue factor. All items of the MH-SF36
loaded higher on the mental health factor (Table 3).
These results were similar using a larger sample includ-
ing SLE, pSS, and HV (data not shown) except for the
item FAS-7 showing a higher loading on the fatigue fac-
tor (0.48) than on the mental factor (0.42).
Comparison of fatigue levels between groups
The FAS score was significantly increased in both SLE
and pSS compared to healthy subjects. Median (IQR)
FAS was 23 (17–32) in SLE, 27 (20–34) in pSS, and 16
(14–18) in HV (p = 0.001). These fatigue findings were
confirmed using the VT-SF36 subscale (median VT score
[IQR] = 45 [23–58] in SLE, 35 [15–50] in pSS, and 70
[50–75] in HV, p = 0.001). There was a good correlation
between the FAS and the VT-SF36 score among all
groups of participants (Table 4). There was a lesser but
significant correlation between FAS and the other sub-
scales of the SF36 in both SLE and pSS. In contrast, HV
showed modest to the non-significant correlation be-
tween FAS and SF-36 subscales other than VT. In the
three groups of participants, no correlation was found
Table 2 Clinical characteristics of systemic lupus erythematosus patients according to global disease activity (n = 73)
Inactive SLE (n = 50) Active SLE (n = 23) p value§
Age, median (IQR) years 46 (35–59) 39 (30–52) 0.20
Female sex (%) 44 (88) 21 (91) 0.68
Caucasian, no. (%) 38 (76) 18 (78) 0.83
Higher education*, no./total (%) 20/39 (51) 10/20 (50) 0.93
Active smoker, no. (%) 9 (18) 8 (35) 0.12
Body mass index, median (IQR) 24 (20–29) 22 (19–24) 0.35
Use of psychiatric medication£, no. (%) 9 (18) 5 (22) 0.75
Disease duration, median (IQR) years 7 (3–15) 6 (3–15) 0.42
History of lupus nephritis, no (%) 19 (38) 6 (26) 0.31
History of neurolupus, no (%) 6 (12) 2 (7) 0.67
SELENA-SLEDAI, median (IQR) score 2 (0–2) 6 (4–10) < 0.001
PGA score, median (IQR) score 0 (0–0) 1 (1–2) < 0.001
Immunomodulators past month, no. (%) 44 (88) 20 (87) 0.90
Antimalarials, no. (%) 37 (74) 15 (65) 0.44
Systemic corticosteroids, no. (%) 26 (52) 13 (57) 0.72
Immunosuppressants, no. (%) 25 (50) 10 (43) 0.60
IQR interquartile range, SLE systemic lupus erythematosus
*Active disease is defined as a Systemic Lupus Erythematosus Disease Activity Index score with the Safety of Estrogens in Lupus Erythematosus National
Assessment modification (SELENA-SLEDAI) ≥ 4 and a Physician’s Global Assessment score (PGA) ≥ 1
£Defined as any antidepressants, antipsychotics, and anxiolytics/hypnotics
§p value < 0.05 is considered significant
Fig. 1 Scree plot of the Fatigue Assessment Scale (FAS) and
its items
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between the total FAS score and demographic features
such as age, sex, ethnicity, educational status, and BMI
(data not shown). Tobacco use was weakly associated
with a higher degree of fatigue in the pSS group (p =
0.024). The use of psychiatric medication was associated
with higher fatigue levels in both SLE (p = 0.002) and
pSS (p = 0.047) patients, but not in HV.
Association of fatigue and disease activity in SLE patients
The median (IQR) FAS score was 31 (20–36) in patients
with active SLE, compared to 22 (15–27) in those with
inactive disease (p = 0.005). In healthy volunteers, the
FAS score was slightly lower than in patients with in-
active SLE (p = 0.05). In contrast, patients with active
disease presented with a significant higher level of
fatigue than HV (p < 0.001) (Fig. 2). No association was
found between fatigue and other clinical parameters
such as the time elapsed from diagnosis to assessment,
number of ACR criteria fulfilled at inclusion, presence of
renal involvement at any time during disease course,
presence of auto-antibodies (anti-dsDNA and anti-SSA/
Ro) at study visit, and damage accrual (SDI score). There
was no difference in levels of fatigue between SLE pa-
tients with or without a history of renal disease (median
[IQR] FAS was 24 [17–32] and 23 [16–31], respectively).
Fatigue was higher in the patients treated with cortico-
steroids (r = 0.27, p = 0.022). There was no difference
when comparing fatigue with the use of other DMARDs.
In a linear regression model, after adjusting for cortico-
steroids and psychiatric medication use at visit, active
disease remained significantly associated with fatigue so
that FAS increased on average by 6.2 points (95%CI 2.2–
10.3, p = 0.003) for each additional point in disease
activity.
Discussion
To the best of our knowledge, ours is the first study that
validates the FAS as a simple and reliable tool to assess
fatigue in SLE. The FAS measures fatigue by means of
10 items including two reverse questions. This fatigue
scale was previously shown to be useful and valid in the
general population, in the working population, and in
sarcoidosis patients. Fatigue is a prominent feature of
SLE, a disease known for its wide range of symptoms.
Brain fog is a common complaint in SLE patients, which
refers to periods of impaired cognition [26] without any
signs of neurolupus. Indeed, only a very few of the
Table 3 Factor loading of the FAS and the MH-SF36 obtained in 73 patients with SLE in a two-factor solution
Items Factor 1 - fatigue Factor 2 - mental health
I am bothered by fatigue (FAS-1) 0.94† 0.10
I get tired very quickly (FAS-2) 0.94† 0.08
I do not do much during the day (FAS-3) 0.75† 0.08
I have enough energy for everyday life (FAS-4) − 0.74† − 0.13
Physically, I feel exhausted (FAS-5) 0.89† 0.01
I have problems starting things (FAS-6) 0.62† − 0.32†
I have problems thinking clearly (FAS-7) 0.37† − 0.51†
I feel no desire to do anything (FAS-8) 0.65† − 0.25
Mentally, I feel exhausted (FAS-9) 0.62† − 0.25
When I am doing something, I can concentrate quite well (FAS-10) − 0.77† − 0.20
Have you been a very nervous person? (SF09B) 0.18 0.97†
Have you felt so down in the dumps that nothing could cheer you up? (SF09C) − 0.05 0.87†
Have you felt calm and peaceful? (SF09D) 0.20 − 0.67†
Have you felt downhearted and low? (SF09F) 0.02 0.91†
Have you been a happy person? (SF09H) 0.17 − 0.68†
FAS Fatigue Assessment Scale, MH-SF36 mental health component of the Short Form 36 health survey questionnaire
†A coefficient factor above 0.3 was considered significant
Table 4 Correlation coefficient between the FAS and the SF-36
subscores
FAS
SF-36 subscores SLE (n = 73) pSS (n = 23) HV (n = 23)
Physical functioning − 0.58* − 0.73* − 0.25
Role physical − 0.59* − 0.58* − 0.32
Role emotional − 0.60* − 0.64* 0.00
Bodily pain − 0.68* − 0.67* 0.23
General health − 0.71* − 0.70* − 0.50*
Vitality − 0.85* − 0.78* 0.85*
Social functioning − 0.67* − 0.47* 0.52*
Mental health − 0.65* − 0.60* − 0.50*
FAS Fatigue Assessment Scale, SF-36 Short Form 36, SLE systemic lupus
erythematosus, pSS primary Sjogren’s syndrome, HV healthy volunteers
*Correlations are significant at p value < 0.05
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patients in this study had overt neurological disease. Fa-
tigue is also a major complaint in other autoimmune
diseases such as pSS. The thin line between cognitive
dysfunction and depression in SLE and pSS makes fa-
tigue assessment a particular challenge in this popula-
tion. Our study shows that the FAS displays solid
psychometric abilities, with an excellent internal
consistency and test-retest reliability. Its convergent val-
idity is supported by the good correlation with the
VT-SF36. Concerning discriminant validity, it is revealed
that fatigue and mental disorders such as depression are
related but distinct constructs.
This cross-sectional study also shows that fatigue mea-
sured by FAS is significantly increased in both SLE and
pSS patients compared to healthy controls. Several au-
thors reported similar results for chronic inflammatory
diseases, including SLE and pSS [27, 28]. In previous
studies, the prevalence of fatigue in SLE subjects varied
from 76 to 90% [3, 29, 30]. By comparing FAS to the
SF-36 subscales, we confirm the relationship between fa-
tigue and various aspects of HRQoL, such as perceived
mental health, emotional state, bodily pain, and social
functioning in both SLE and pSS. We found that fatigue
levels were higher in patients using psychiatric medica-
tion. Whether fatigue is the cause or the consequence of
mental health issues and prescribed psychiatric medica-
tion in these patients remains to be established. SLE pa-
tients in our study differed from those with pSS in terms
of disease duration from diagnosis, which was signifi-
cantly shorter for pSS. On the other hand, pSS has a
more insidious disease course than SLE. Diagnosis of
pSS is often delayed by years and the duration of symp-
toms difficult to establish. This may explain why the
time elapsed since pSS and SLE diagnosis in our study
had no influence on the measured fatigue levels and re-
flects our clinical impression of long-standing fatigue in
most patients suffering from these conditions. Moreover,
we show that patients with active SLE have significantly
more fatigue than healthy controls, whereas this differ-
ence is much less pronounced in those with inactive
SLE. The association between fatigue and disease activity
in SLE is controversial. Some authors reported a lack of
association between disease activity and the Fatigue Se-
verity Score [30–32]. Others, however, were able to show
that fatigue increases with SLE activity, although to vari-
ous degrees [3, 14, 33]. In the present study using two
global scores (SELENA-SLEDAI and PGA) to ascertain
SLE disease activity, we demonstrate a clear positive cor-
relation with fatigue. Interestingly, patients with active
SLE displayed a similar degree of fatigue than those with
pSS. This observation amplifies the need for further in-
vestigation of immune factors that could contribute to
fatigue in both active pSS and SLE. Recently, Petri et al.
demonstrated a significant decrease in fatigue and dis-
ease activity in SLE patients treated with blisibimod, a
selective inhibitor of B cell activating factor, in a phase
2b study. The authors found a weak correlation between
disease activity and fatigue and concluded that this
symptom appears to be closely related to immune dys-
function [33, 34]. Others have found that the use of IL-6
Fig. 2 Fatigue Assessment Scale (FAS) scores in 73 patients with systemic lupus erythematosus (SLE) according to disease activity and controls
with primary Sjogren’s syndrome or in good health. SLE systemic lupus erythematosus, FAS Fatigue Assessment Scales (ranges from 10 – no
fatigue to 50 – extreme fatigue), pSS primary Sjogren’s syndrome, Healthy healthy volunteers. Plots represent the individual values (diamonds),
the median score, and the IQR for each group. *p < 0.05; **< 0.001
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blocking agents has a favorable impact on fatigue in SLE
[35]. These findings could be explained by the impact of
pro-inflammatory cytokines on the central nervous sys-
temic with induction of illness behavior, expressed in
symptoms such as fatigue and anhedonia [36]. The relief
of fatigue after the use of various biological agents sup-
ports a relationship between fatigue and inflammation
due to ongoing disease activity. We did not find any as-
sociation of fatigue with traditional markers, such as
auto-antibodies. This underlines the need for further
studies to assess fatigue levels in relation to circulating
cytokines and novel biomarkers in autoimmune disease.
Our study has some limitations. We did not assess
additional factors potentially contributing to fatigue,
such as sleep disorders, depression, and physical activity.
Our study is cross-sectional and does not allow the de-
termination of the sensitivity to change. Longitudinal
studies with FAS are needed to assess variations in fa-
tigue, and its causes and its impact on health-related
quality of life and working capacity both in SLE and pSS.
Conclusion
In conclusion, this study validates the FAS as a simple
and reliable tool to assess fatigue in patients with SLE
and shows a close and positive correlation of fatigue
with disease activity, independently from corticosteroid
use and psychiatric medication.
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